Relationship Between Serum N/OFQ and Brain-heart Syndrome

Relationship Between Serum N/OFQ and Cerebral Cardiac Syndrome After Stroke

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05344794

Enrollment

120

Registered

2022-04-25

Start date

2023-05-01

Completion date

2023-10-31

Last updated

2023-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral-Cardiac Syndrome

Brief summary

Choosing the neurology patients in the Second Hospital of Shanxi Medical University, diagnosed with patients with cerebral syndrome into the experimental group; patients who did not have cerebral syndrome included in the control group, and all selected people had no intimate relationship with each other.Specimen collecting control group and the study group serum inflammatory factor IL-6, solvent peptide and catecholamine content. The difference between the two groups of data was observed.According to the literature, it is guess: The solitary peptide content of the experimental group will be higher than the control group, and is positively correlated with IL-6, catecholamine content.The difference was statistically significant.

Interventions

DIAGNOSTIC_TESTEnzyme-linked immunosorbent assay

Serum N/OFQ , IL-6 and NE levels were detected.

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

45 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Diagnostic criteria in compliance with cerebral syndrome * Acute ischemic stroke patients in line with the Chinese Acute Ischemic Stroke Treatment Guide 2018 related diagnostic criteria * There is no intimate relationship between all selected people and knows this study, and signs informed consent

Exclusion criteria

* Heart-type cerebral infarction, hemorrhagic stroke, brain tumor and past intracranial hemorrhage * Complicated with severe cardiovascular complications (such as coronary heart disease, acute coronary syndrome, acute myocardial infarction, chronic heart failure, atrial fibrillation, etc.) * Complicated with severe liver and kidney dysfunction (such as coagulous dysfunction, cirrhosis, nephrotic syndrome , Renal failure, etc.) * Complicated with severe diabetes complications (such as diabetic nephropathy, diabetic foot, diabetic acidosis, high blood sugar hypertonic state, diabetes coronary heart disease, etc.) * Complicated with Psychological disease * Complicated with chronic obstructive pulmonary disease(COPD) * BMI\> 40

Design outcomes

Primary

Measure	Time frame	Description
N/OFQ	24 hours	Serum N/OFQ levels
IL-6	24 hours	Serum IL-6 levels
NE	24 hours	Serum NE levels

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026